Organization
USC Norris Comprehensive Cancer Center
11 abstracts
Abstract
Outcome of patients with primary CNS lymphoma treated with methotrexate based regimens: A retrospective study.Org: USC Norris Comprehensive Cancer Center, University of Southern California/Los Angeles General Internal Medicine Residency Program,
Abstract
Final results from phase I study of PSCA-targeted chimeric antigen receptor (CAR) T cells in patients with metastatic castration resistant prostate cancer (mCRPC).Org: City of Hope Comprehensive Cancer Center, City of Hope National Medical Center, City of Hope Beckman Research Institute, USC Norris Comprehensive Cancer Center, University of Southern California Marshall School of Business,
Abstract
Determinants of resistance to nivolumab (nivo) monotherapy investigated through genomic and transcriptomic analysis of renal cell carcinoma (RCC) tumors from the HCRN GU16-260 study.Org: School of Medicine, Zhejiang University, Hangzhou, China, Yale University, New Haven, CTI BioPharma, Keck School of Medicine of the University of Southern California,
Abstract
Genomic landscapes to characterize mismatch-repair deficiency (dMMR)/microsatellite instability-high (MSI-H) gastrointestinal (GI) cancers stratified by tumor mutation burden (TMB).Org: Norris Comprehensive Cancer Center, Keck School of Medicine of the University of Southern California, University of Southern California Marshall School of Business, Caris Life Sciences, Irving, TX, Department of Preventive Medicine,
Abstract
HER2 testing in the MOUNTAINEER trial: Analysis of treatment response based on central HER2 assessment using IHC/ISH and NGS.Org: Duke University Medical Center, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Grande Ospedale Metropolitano Niguarda and Università degli Studi di Milano,
Abstract
A phase 1 study of AGEN2373, a novel CD137 agonist antibody designed to avoid hepatoxicity, in patients with advanced solid tumors.Org: Mary Crowley Cancer Research Center, Dallas, Next Oncology Virginia and Virginia Cancer Specialists, San Antonio Breast Cancer Symposium, Northwell Health Cancer Institute,
Abstract
Bone biomarkers and subsequent survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): Results from the phase III SWOG S1216 trial of androgen deprivation +/- orteronel.Org: University of California Davis Comprehensive Cancer Center, SWOG Statistical Center, Western Human Nutrition Research Center, WHNRC, Davis Comprehensive Cancer Center,
Abstract
Effects of virtual reality on pain and anxiety in patients with cancer undergoing bone marrow biopsy.Org: USC/Norris Comprehensive Cancer Center, USC Norris Comprehensive Cancer Center,
Abstract
A randomized, open-label, phase II study of high-dose interleukin 2 vs high-dose interleukin 2 plus entinostat in renal cell carcinoma.Org: University at Buffalo Jacobs School of Medicine and Biomedical Sciences, USC Norris Comprehensive Cancer Center, Keck Medicine of USC, Nebraska Cancer Specialists - Midwest Cancer Center, Rush University Medical Center,
Abstract
BELIMUMAB (BMAB), A FULLY HUMAN MONOCLONAL ANTIBODY TO B-LYMPHOCYTE STIMULATOR (BLYS), SHOWS BIOACTIVITY AND REDUCES SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITYOrg: LBSL02 Study Grp, Cedars-Sinai Comprehensive Cancer Center, UCLA Department of Medicine, Los Angeles Medical Center, UA AHSC,
Abstract
BELIMUMAB (FULLY HUMAN MONOCLONAL ANTIBODY TO BLYS) IMPROVED OR STABILIZED SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DISEASE ACTIVITY AND REDUCED FLARE RATE DURING 3 YEARS OF THERAPYOrg: NSLIJHS, Lake Success, NY, Lake Success, NY, JHU, Baltimore, Cedars-Sinai Comprehensive Cancer Center,